Cancer Monoclonal Antibodies Market Worth USD 159.8 BN By 2030 | CAGR: 11.4%

According to Nova one advisor's recent analyses the Cancer Monoclonal Antibodies Market is valued at USD 62.4 Billion in 2021, and would all set to rocket up to USD 159.8 Billion by 2030, at a CAGR of 11.4% during the forecast period from 2022 to 2030

Get the Free Sample Copy of Report@

Key Takeaways:

  • By Type, the U.S. Cancer Monoclonal Antibodies market was valued at USD 21.6 Billion in 2021 and expected to witness growth at a CAGR of 9.8% from 2022 to 2030.
  • By type, the humanized segment held a larger share of the market in 2021 owing to factors such as, low cost, availability, and quick production time for mouse monoclonal antibodies. However, the human segment is expected to hold the highest CAGR during the forecast period due to an increase in the number of product approvals and product launches
  • The blood cancer application segment held a significant revenue share in 2021 owing to an increase in the prevalence of hematological disorders along with a robust pipeline. In addition, the lung cancer segment is poised to expand at the highest CAGR during the forecast period
  • In 2021, the hospital segment was the leading end-user segment due to an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in the facility drives the patient preference
  • North America dominated the global market in 2021, due to the strategic activities of key market players, increasing cancer cases, and supportive government efforts in this region
  • In Asia Pacific, the market is expected to grow considerably in the future due to the increasing number of international and national collaborations among entities, especially those in developed and developing countries

Immediate Delivery Available | Buy this Premium Research Report@

Report Scope of the Cancer Monoclonal Antibodies Market

Report Coverage


Market Size

US$ 159.8 Billion by 2030

Growth Rate

CAGR of 11.4% from 2022 to 2030

Largest Market

North America

Fastest Growing Market

Asia Pacific

Base Year


Forecast Period

2022 to 2030

Segments Covered

 Type, application, end-user, and Region,


Monoclonal antibody-based immunotherapy is a major element of cancer therapy besides surgery, chemotherapy, and radiation. mAbs have been recognized as one of the utmost successful therapeutic approaches for both solid tumors and hematologic malignancies in the last 20 years. The rising prevalence of cancer and increasing drug approvals along with a robust pipeline are the key factors augmenting the market growth. Millions of people globally stand to benefit both from the current monoclonal antibody-based therapies and those that are in development.

Moreover, mAbs have reduced side effects on the patient’s body when compared to chemotherapy. Furthermore, the growing adoption of cost-efficient biosimilar mAbs by oncologists and medical practitioners will further provide a boost to the growth of the market during the forecast period. In March 2020, the WHO designated COVID-19 as a pandemic. This outbreak has considerably affected both the world and the U.S. markets. In response to the COVID-19 outbreak, governments of many cities, counties, states, and other geographic regions have taken protective or preventative actions, such as imposing restrictions. As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials.

Moreover, the reduced access to health care systems to contain the pandemic resulted in a sharp decline in cancer screening. For instance, breast cancer screening saw an 87% decline in April 2020 compared to the average for the same month over the last five years. Many cancer patients had to delay or postpone their cancer treatment, which led to concerns about timely access to cancer treatments and disease recurrence or cancellation of cancer treatments. Cancer is a class of chronic diseases categorized by uncontrolled cell growth. The increasing number of cancer cases is anticipated to increase the demand for monoclonal antibodies and propel market growth.

According to the American Society of Clinical Oncology, by the end of 2022, there will be a projected 1.9 million diagnosed cancer cases and 609,360 deaths in the U.S. In addition, estimates by the same source projected that in 2020, an estimated 176,000 people globally were diagnosed with multiple myeloma. In 2022, it is projected that more than 34,000 individuals will be diagnosed with multiple myeloma, and above 12,000 people will die in the U.S. Over the past couple of years, the US FDA has approved more than a dozen monoclonal antibodies for treating various types of cancer. As scientists have discovered more antigens connected to cancer, they have been able to develop monoclonal antibodies against several cancer types.

In addition, clinical trials of newer monoclonal antibodies are now being carried out for various types of cancer. mAbs present a huge opportunity for the treatment of cancer due to their specificity. Their use will witness increasing demand during the forecast period, as science determines more and more novel targets in cancer cells. Many types of tumors are presently being treated with these novel biological drugs. Treatment standards involving monoclonal antibodies will continue to progress and have the probability to offer therapeutic options for cancer patients in the coming years.

Regional Insights

North America dominated the cancer monoclonal antibodies market with a share of 37.6% in 2021. Strategic activities are key factors influencing the market growth. For instance, in September 2020, AbbVie and I-Mab signed a broad, international partnership agreement for the commercialization and development of lemzoparlimab, an advanced anti-CD47 monoclonal antibody discovered and developed by I-Mab for multiple cancers treatment. The partnership also allows for future collaboration on CD47-associated therapeutic agents.

Asia Pacific is estimated to be the fastest-growing region owing to increasing efforts by global firms to penetrate this emerging market to capture a higher share. An increasing number of international and national collaborations among entities, especially those in developed and developing countries, is expected to propel the market. In addition, an increase in the adoption of biosimilars in the region will further offer lucrative opportunities in the review period. For instance, in recent years, China’s biosimilar drug industry has established rapidly. By the end of 2019, the country had the maximum number of biosimilar drugs in research, with 391 biosimilar drugs in the research and development pipeline. As of December 2020, 11 biosimilar drugs had been accepted for marketing in China, comprising 6 drugs for oncology

Some of the prominent players in the Cancer Monoclonal Antibodies Market include:

  • F. Hoffmann-La Roche Ltd.
  • Bristol Myers Squibb Co.
  • Merck & Co.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Amgen, Inc.
  • Novartis AG
  • AstraZeneca plc
  • Eli Lilly and Company
  • AbbVie

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cancer Monoclonal Antibodies market

  • Type
    • Humanized
    • Human
    • Chimeric
    • Murine
  • Application
    • Blood Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Colorectal Cancer
    • Liver Cancer
    • Others
  • End-user
    • Hospitals
    • Research Institutes
    • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Full Report is Ready | For Purchase Inquiry@

You can place an order or ask any questions, please feel free to| +1 9197 992 333






Back to news